Compass Pathways (NASDAQ:CMPS) Stock Gets Price Target Reduction from Wells Fargo & Company

Compass Pathways (NASDAQ:CMPS) had its price objective decreased by Wells Fargo & Company from $13.00 to $10.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 20.35% from the company’s current price.

CMPS has been the topic of several other reports. Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a research report on Wednesday, July 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Morgan Stanley boosted their price objective on Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded Compass Pathways from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.14.

Compass Pathways Price Performance

Compass Pathways stock traded down $0.28 during mid-day trading on Wednesday, reaching $8.31. 1,625,511 shares of the company’s stock traded hands, compared to its average volume of 3,487,739. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock has a 50 day moving average of $12.70 and a two-hundred day moving average of $10.39. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -1.81 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. Equities analysts forecast that Compass Pathways will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Compass Pathways

Hedge funds and other institutional investors have recently made changes to their positions in the company. North Star Investment Management Corp. lifted its holdings in shares of Compass Pathways by 23.9% in the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after acquiring an additional 1,800 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the last quarter. WINTON GROUP Ltd grew its holdings in Compass Pathways by 20.1% during the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock valued at $253,000 after purchasing an additional 3,000 shares during the last quarter. Ancora Advisors LLC purchased a new stake in Compass Pathways in the 2nd quarter worth about $43,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Compass Pathways by 15.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after purchasing an additional 3,249 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Trending Headlines about Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Compass reported a third-quarter loss of $0.31 per share, narrower than analysts’ $0.39 loss estimate. The company also said it expects to complete its COMP360 New Drug Application submission within two weeks and outlined a potential 30-to-60-day FDA review target. Earnings report FDA timeline report
• Positive Sentiment: A survey cited in coverage found that 90% of interventional psychiatrists surveyed would be willing to prescribe COMP360, suggesting potential clinician interest if the treatment is approved. Long-term investor takeaways
• Positive Sentiment: Analyst support provided another favorable signal: BTIG reaffirmed its Buy rating with a $25 price target, Oppenheimer reiterated Outperform, and Jefferies said Compass’ clinical data could support pricing power. BTIG rating Oppenheimer rating
• Negative Sentiment: Competition remains a key risk. A rival’s NDA submission had recently pressured CMPS, contributing to a selloff before the earnings-related rebound. Stifel described the Usona situation as “extremely atypical,” but the competitive implications remain uncertain. Stock rebound and competition report Stifel commentary

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.